Letters to the Editor
5 November 2024
Vol. 2 No. 3 (2024)
https://doi.org/10.4081/cardio.2024.48

Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Mavacamten, obstructive hypertrophic cardiomyopathy
2220
Views
542
Downloads
0
HTML

Authors

Ahmad Shabbir
ahmadshabbir4623@gmail.com
Department of Cardiology, Nishtar Medical University and Hospital, Multan, Pakistan.
Laiba Yumn
Department of Cardiology, Nishtar Medical University and Hospital, Multan, Pakistan.
Esha Khan
Department of Cardiology, Nishtar Medical University and Hospital, Multan, Pakistan.

Dear Editor,

Obstructive hypertrophic cardiomyopathy (oHCM) is a hereditary cardiac condition, affecting 1 in about 500 individuals, characterized by an atypical thickening of the heart muscle, specifically the interventricular septum...

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: clinical update. JACC Heart Fail 2018;6:364-375. DOI: https://doi.org/10.1016/j.jchf.2018.02.010
Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-33. DOI: https://doi.org/10.1093/eurheartj/ehad637
Zampieri M, Argirò A, Marchi A, et al. Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy. Curr Cardiol Rep 2021;23:79. DOI: https://doi.org/10.1007/s11886-021-01508-0
Makhija M, Bansal A, Jakhar P, Sharma L, Kumar S, Gupta D. Mavacamten: a novel avenue towards hypertrophic obstructive cardiomyopathy. Int J Basic Clin Pharmacol 2024;13:568-72. DOI: https://doi.org/10.18203/2319-2003.ijbcp20241661
Yacoub MS, El-Nakhal T, Hasabo EA, et al. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev 2024;29:479-96. DOI: https://doi.org/10.1007/s10741-023-10375-6
Hegde SM, Lester SJ, Solomon SD, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2518-32. DOI: https://doi.org/10.1016/j.jacc.2021.09.1381

How to Cite



1.
Shabbir A, Yumn L, Khan E. Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiol [Internet]. 2024 Nov. 5 [cited 2025 Aug. 13];2(3). Available from: https://www.globalcardiology.info/site/article/view/48
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.